Therefore, if the significant sensitivity and specificity of PSMA-PET scans seen in prostate cancer [18] could be replicated in gliomas, PSMA PET scans could be a powerful predictive tool for bevacizumab response. The gene discussed is FOLH1; the disease is glioma.